CYP2C9 and non-small cell lung carcinoma: Sausville et al. reported that mice injected with human NSCLC cells expressing CYP2C9*2 and *3 variants produced significantly lower EETs resulting in smaller and less vascularized tumors compared with mice injected with human NSCLC cells expressing wildtype CYP2C9*1 (Sausville et al., 2018).